PDF下载 ( 1972 KB)
Clinical features of patients with pancreatic neuroendocrine tumor and influencing factors for prognosis
-
摘要:
目的探讨胰腺神经内分泌肿瘤（PNET）患者的临床特征及预后影响因素。方法收集2012年3月-2019年4于上海交通大学附属第一人民医院病理确诊为PNET的54例患者临床资料,分析患者临床、病理、影像学特征及预后情况。计数资料组间比较采用χ2检验或Fisher精确检验。采用Kaplan-Merier法进行生存分析,并用log-rank进行组间差异检验。结果 54例PNET患者中,男19例（35. 2%）,女35例（64. 8%）;无功能性PNET 47例（87. 0%）,功能性PNET 7例（13. 0%）; TNMⅠ、Ⅱ、Ⅲ、Ⅳ期分别有17例（31. 5%）、26例（48. 1%）、9例（16. 7%）、2例（3. 7%）;世界卫生组织病理分级G1、G2、G3期分别有24例（46. 2%）、22例（42. 3%）、6例（11. 5%）。CT（χ2=8. 250,P=0. 010）和MRI（χ2=6. 048,P=0. 031）检查评估结果示肿瘤边界不清的患者术后复发和病死率更高。患者总生存期为1～86个月,5年生存率为9...
Abstract:Objective To investigate the clinical features of patients with pancreatic neuroendocrine tumor( PNET) and the influencing factors for prognosis. Methods A retrospective analysis was performed for the clinical data of 54 patients with pathologically confirmed PNET in The First Affiliated People's Hospital of Shanghai Jiao Tong University from March 2012 to April 2019,and clinical,pathological,and imaging features and prognosis were analyzed. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. The Kaplan-Meier method was used for survival analysis,and the log-rank test was used for comparison between groups.Results Among the 54 patients,there were 19 male patients( 35. 2%) and 35 female patients( 64. 8%). Of all patients,47( 87. 0%)had non-functional tumors and 7( 13. 0%) had functional tumors. There were 17 patients( 31. 5%) with TNM stage Ⅰ tumor,26 patients( 48. 1%) with stage Ⅱ tumor,9 patients( 16. 7%) with stage Ⅲ tumor,and 2 patients( 3. 7%) with stage Ⅳ tumor. According to the World Health Organization pathological grade,24 patients( 46. 2%) had G1 tumor,22( 42. 3%) had G2 tumor,and 6( 11. 5%) had G3 tumor. The patients with unclear boundary of tumor on CT( χ2= 8. 250,P = 0. 010) and MRI( χ2= 6. 048,P = 0. 031) tended to have higher postoperative recurrence rate and mortality rate. Overall survival time ranged from 1 to 86 months,with a 5-year survival rate of92. 0% and a disease-free survival time of 1-71 months. The univariate analysis showed that TNM stage( χ2= 9. 572,P = 0. 023),pathological grade( χ2= 7. 506,P = 0. 023),surgical margin invasion( χ2= 15. 123,P < 0. 001),lymph node metastasis( χ2= 4. 716,P =0. 030),and distant metastasis( χ2= 5. 534,P = 0. 019) were associated with overall survival time in the patients with PNET. Conclusion PNET patients with unclear tumor boundary on CT and MRI tend to have poor prognosis. TNM stage,pathological grade,surgical margin invasion,lymph node metastasis,and distant metastasis are closely associated with the prognosis of patients with PNET.
-
Key words:
- pancreatic neoplasms /
- neuroendocrine tumors /
- disease attributes /
- prognosis
-
[1] REID MD,BALCI S,SAKA B,et al. Neuroendocrine tumors of the pancreas:Current concepts and controversies[J]. Endocr Pathol,2014,25(1):65-79. [2] SUN HT,ZHANG SL,LIU K,et al. MRI-based nomogram estimates the risk of recurrence of primary nonmetastatic pancreatic neuroendocrine tumors after curative resection[J]. J Magn Reson Imaging,2019,50(2):397-409. [3] BASHIR MR,GUPTA RT. MDCT evaluation of the pancreas:Nuts and bolts[J]. Radiol Clin North Am,2012,50(3):365-377. [4] BOSMAN FT,CARNEIRO F,HRUBAN RH,et al. WHO classification of tumors of the digestive system[M]. 4th edition. Lyon:International Agency for Research on Cancer,2010. [5] BRIERLEY JD,GOSPODAROWICZ K,WITTEKIND C,et al.TNM classification of malignant tumors[M]. 8th edition. UK:Wiley Blackwell,2017. [6] ZHANG TP,QIU JD,FENG MY,et al. Progress and controversy on the treatment of incidental non-functioning pancreatic neuroendocrine tumors[J]. Chin J Dig Surg,2018,17(7):666-670.(in Chinese)张太平，邱江东，冯梦宇，等．偶发无功能胰腺神经内分泌肿瘤的治疗进展与争议[J]．中华消化外科杂志，2018,17(7):666-670. [7] DE ROBERTIS R,CINGARLINI S,TINAZZI MARTINI P,et al.Pancreatic neuroendocrine neoplasms:Magnetic resonance imaging features according to grade and stage[J]. World J Gastroenterol,2017,23(2):275-285. [8] GUO CG,REN S,CHEN X,et al. Pancreatic neuroendocrine tumor:Prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance[J]. Cancer Manag Res,2019,11:1933-1944. [9] KIM DW,KIM HJ,KIM KW,et al. Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT:Comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour[J]. Eur Radiol,2015,25(5):1375-1383. [10] KIM JH,EUN HW,KIM YJ,et al. Pancreatic neuroendocrine tumour(PNET):Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma[J]. Eur Radiol,2016,26(5):1338-1347. [11] CANELLAS R,LO G,BHOWMIK S,et al. Pancreatic neuroendocrine tumor:Correlations between MRI features,tumor biology,and clinical outcome after surgery[J]. J Magn Reson Imaging,2018,47(2):425-432. [12] ZHAO XD,TIAN XD,YANG YM. Diagnosis and surgical treatment of pancreatic neuroendocrine neoplasms[J]. Chin J Hepatobiliary Surg,2017,23(8):505-508.(in Chinese)赵旭东，田孝东，杨尹默．胰腺神经内分泌肿瘤的诊断与外科治疗[J]．中华肝胆外科杂志，2017,23(8):505-508. [13] YANG M,ZHANG Y,ZENG L,et al. Prognostic validity of the American Joint Committee on Cancer eighth edition TNM staging system for surgically treated and well-differentiated pancreatic neuroendocrine tumors:A comprehensive analysis of254 consecutive patients from a large Chinese institution[J].Pancreas,2019,48(5):613-621. [14] PAVEL M,O’TOOLE D,COSTA F,et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal,pancreatic,bronchial neuroendocrine neoplasms(NEN)and NEN of unknown primary site[J]. Neuroendocrinology,2016,103(2):172-185. [15] YAO JC,PAVEL M,LOMBARD-BOHAS C,et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors:Overall survival and circulating biomarkers from the randomized,phase III RADIANT-3 study[J]. J Clin Oncol,2016,34(32):3906-3913. [16] FAIVRE S,NICCOLI P,CASTELLANO D,et al. Sunitinib in pancreatic neuroendocrine tumors:Updated progressionfree survival and final overall survival from a phase III randomized study[J]. Ann Oncol,2017,28(2):339-343. [17] IMHOF A,BRUNNER P,MARINCEK N,et al. Response,survival,and long-term toxicity after therapy with the radiolabeled somatostatin analogue[90Y-DOTA]-TOC in metastasized neuroendocrine cancers[J]. J Clin Oncol,2011,29(17):2416-2423. [18] LUO Q,LIU YN,MA HY,et al. Analysis of diagnosis,therapy and prognosis factors of 103 patients with pancreatic neuroendocrine tumors[J]. Chin J Surg,2017,55(10):755-759.(in Chinese)罗乔，刘艳楠，马洪运，等．胰腺神经内分泌肿瘤103例诊治经验及预后因素分析[J]．中华外科杂志，2017,55(10):755-759. [19] SHEN C,DASARI A,CHU Y,et al. Clinical,pathological,and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors[J]. Ann Oncol,2017,28(7):1582-1589. [20] YANG M,TIAN B,ZHANG Y,et al. Epidemiology,diagnosis,surgical treatment and prognosis of the pancreatic neuroendocrine tumors:Report of 125 patients from one single center[J]. Indian J Cancer,2015,52(3):343-349. [21] ZHANG P,LI YL,QIU XD,et al. Clinicopathological characteristics and risk factors for recurrence of wel-differentiated pancreatic neuroendocrine tumors after radical surgery:A case-control study[J]. World J Surg Oncol,2019,17(1):66. [22] BALLIAN N,LOEFFLER AG,RAJAMANICKAM V,et al. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms[J]. HPB(Oxford),2009,11(5):422-428. [23] FISHER AV,LOPEZ-AGUIAR AG,RENDELL VR,et al. Predictive value of chromogranin A and a pre-operative risk score to predict recurrence after resection of pancreatic neuroendocrine tumors[J]. J Gastrointest Surg,2019,23(4):651-658. 期刊类型引用(16)
1. 巴明玉，潘研，王娴，陈亚琳，燕树勋. 强肝胶囊对非酒精性脂肪肝肥胖患者糖脂代谢水平及肝功能的影响. 中医学报. 2024(02): 416-420 . 
百度学术2. 范文，郑垂仰，周旋，孔怡琳，潘丰满，杨钦河，张玉佩. 6种中成药治疗非酒精性脂肪性肝病有效性和安全性的网状Meta分析. 中药新药与临床药理. 2023(11): 1612-1622 . 百度学术3. 崔姗姗，刘英，江霞. 非酒精性脂肪性肝病与胰岛素抵抗的研究进展. 医学信息. 2022(10): 66-69 . 百度学术4. 舒祥兵，操颖，顾晔，杨志新，季光，张莉. 强肝胶囊促进肝糖原合成降低大鼠高血糖的机制研究. 上海中医药大学学报. 2021(03): 45-51 . 百度学术5. 贾英杰，张晓博，张新元，杨红霞，郭争荣. 强肝胶囊对猪血清诱导大鼠肝纤维化的治疗作用. 河北医药. 2021(20): 3104-3107 . 百度学术6. 朱丹，孙婷婷，陈兰羽，谢铮. 脂肪性肝病中医药认识. 辽宁中医药大学学报. 2020(05): 70-73 . 百度学术7. 崔翔，刘玲兰，华鹏，郭薇，薛敬东. 从脾论治非酒精性脂肪性肝病的体会与研究概况. 中医临床研究. 2020(14): 136-138 . 百度学术8. 郭明升，刘娟，郭英杰，籍芳华，郝艳爽. 阿托伐他汀联用脂康颗粒或强肝胶囊用于脑梗死二级预防效果比较. 现代中西医结合杂志. 2020(22): 2400-2404+2446 . 百度学术9. 王秀琴. 强肝胶囊联合甘草酸二铵肠溶胶囊治疗非酒精性脂肪肝的效果. 河南医学研究. 2019(06): 1089-1091 . 百度学术10. 黄静，陈湘清，郭东升，吴奋. 同步抗感染治疗对合并幽门螺杆菌感染非酒精性脂肪肝病患者治疗结局的影响研究. 重庆医学. 2018(01): 97-100 . 百度学术11. 陈少颖，易新宇，周小博，张荣臻. 中医药治疗非酒精性脂肪肝的研究进展. 大众科技. 2018(06): 68-70 . 百度学术12. 周桃梅，杨上文，汪剑波. 强肝胶囊联合二甲双胍治疗非酒精性脂肪肝的疗效及其对Nod样受体-3炎症小体的影响. 中国医院统计. 2018(03): 206-208 . 百度学术13. 柳琳琳，毛德文，吕建林，黄瑞. 强肝胶囊对非酒精性脂肪性肝病患者疗效及安全性的Meta分析. 中成药. 2018(08): 1715-1720 . 百度学术14. 李滨，张佳圆，王凤永，李春晖，齐丽韫，王玉华，赵培利. 胆宁片治疗非酒精性脂肪肝临床效果及对血脂、肝功能和肝纤维化的影响. 解放军医药杂志. 2018(10): 93-96 . 百度学术15. 朱紫馨，祝丽丽，程明亮. 同步抗感染治疗非酒精性脂肪肝合并幽门螺杆菌感染的效果观察. 临床合理用药杂志. 2018(31): 58-59 . 百度学术16. 李军祥，王允亮，郭一，谢添弘. 中医药治疗非酒精性脂肪性肝病专题笔谈. 中国中西医结合消化杂志. 2017(11): 801-804 . 百度学术其他类型引用(13)
-
百度学术
下载:
